SCHEMBL6908047

SCHEMBL6908047

O=CC(c1cc(OCc2ccc(F)cc2)ccc1I)c1cc(OCc2ccc(F)cc2)ccc1I

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.51
MAOB P27338 14/20 0.50
MAOA P21397 4/20 0.50
NR4A2 P43354 2/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
PARP10 Q53GL7 1/20 0.43
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
PKM P14618 1/20 0.42
CYP2C19 P33261 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4420136 0.77 APP (0.53) APPMAOBMAOANR4A2CA12
SCHEMBL6472275 0.70 MAOB (0.60) APPMAOBMAOANR4A2MEN1
SCHEMBL4418983 0.70 NR4A2 (0.54) APPMAOBMAOANR4A2PARP10
SCHEMBL27550091 0.70 MAOB (0.80) APPMAOBNR4A2CA12CA1
SCHEMBL14117266 0.70 MAOB (0.60) APPMAOBMAOANR4A2MEN1
SCHEMBL6461372 0.69 MAOB (0.56) APPMAOBMAOANR4A2PARP10
SCHEMBL9440467 0.69 APP (1.00) APPMAOBNR4A2
SCHEMBL27542544 0.68 MAOB (0.55) APPMAOBMAOANR4A2PARP10
SCHEMBL865238 0.68 MAOB (0.67) APPMAOBMAOANR4A2CA12
SCHEMBL20804354 0.68 MAOB (0.67) APPMAOBMAOANR4A2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1310890-C Isoquinoline derivatives HOFFMANN LA ROCHE (CH) 2007-04-18 CN disclosed
CN-1649844-A Isoquinoline derivatives HOFFMANN LA ROCHE (CH) 2005-08-03 CN disclosed
US-6818774-B2 2-(S)-(6-(4-FLUORO-BENZYLOXY)-3-OXO-3,4-DIHYDRO-1H-ISOQUINOLIN -2-YL)- PROPIONAMIDE FOR EXAMPLE; ALZHEIMER'S DISEASE OR SENILE DEMENTIA HOFFMAN-LA ROCHE INC. 2004-11-16 US disclosed
US-20030225122-A1 2-(S)-(6-(4-fluoro-benzyloxy)-3-oxo-3,4-dihydro-1H-isoquinolin -2-yl)- propionamide for example; Alzheimer's disease or senile dementia HOFFMANN-LA ROCHE INC. 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225122-A1 2-(S)-(6-(4-fluoro-benzyloxy)-3-oxo-3,4-dihydro-1H-isoquinolin -2-yl)- propionamide for example; Alzheimer's disease or senile dementia MAOB, MAOA, BACE2 APP 8/4885MAOB 1/4885MAOA 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.